1. Home
  2. RFIL vs SPRO Comparison

RFIL vs SPRO Comparison

Compare RFIL & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RF Industries Ltd.

RFIL

RF Industries Ltd.

HOLD

Current Price

$13.25

Market Cap

191.3M

Sector

Technology

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.24

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFIL
SPRO
Founded
1979
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
191.3M
156.3M
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
RFIL
SPRO
Price
$13.25
$1.24
Analyst Decision
Hold
Analyst Count
1
0
Target Price
$11.25
N/A
AVG Volume (30 Days)
231.7K
1.7M
Earning Date
06-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
101.59
111.81
EPS
0.07
N/A
Revenue
$55,325,000.00
$66,802,000.00
Revenue This Year
$9.65
N/A
Revenue Next Year
$6.40
$300.00
P/E Ratio
$187.86
N/A
Revenue Growth
10.22
39.24
52 Week Low
$5.54
$1.08
52 Week High
$22.30
$3.08

Technical Indicators

Market Signals
Indicator
RFIL
SPRO
Relative Strength Index (RSI) 46.55 32.73
Support Level $13.10 $1.10
Resistance Level $13.50 $1.28
Average True Range (ATR) 0.83 0.07
MACD 0.28 0.04
Stochastic Oscillator 82.62 63.31

Price Performance

Historical Comparison
RFIL
SPRO

About RFIL RF Industries Ltd.

RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: